Oncopeptides presents new scientific data at European Myeloma Network Meeting
April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company presents new scientific data on melflufen at the European Myeloma Network meeting in Amsterdam on April 20. The data includes one abstract on health-related quality of life outcomes from the phase 3 OCEAN study, and one abstract from the phase 3 LIGHTHOUSE study.
“Relapsed refractory multiple myeloma (RRMM) is associated with severe symptoms including pain, fatigue, physical and emotional functioning, and most patients experience impaired health-related quality of life (HRQoL),” says Fredrik Schjesvold, MD, Head of Oslo Myeloma Center. “The results from OCEAN are important since HRQoL was maintained throughout the treatment with melflufen plus dexamethasone and was similar to the outcome from the treatment with pomalidomide plus dexamethasone.”
“Data from the LIGHTHOUSE study is very encouraging and clearly indicates that the combination of melflufen plus daratumumab has a clinical benefit in patients with RRMM,” says María-Victoria Mateos, MD, PhD, from Salamanca’s University Hospital Haematology Department, and Lead Investigator of the LIGHTHOUSE study. “Multiple myeloma is still an incurable disease for most patients, and we welcome additional evidence on how to combine treatment options with different mode of actions in clinical practice.”
Below is a brief description of the abstracts that have been accepted by the European Myeloma Network. The abstracts are available online through the following link, click here.
|Scientific abstracts||First author||Publication|
|Patient-reported outcomes (pro) in relapsed/refractory multiple myeloma (RRMM) treated with melflufen and dexamethasone (dex) or pomalidomide (pom) and dex: analyses from the phase 3 ocean study.||Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital||Poster P 38|
|Lighthouse (op-108): melflufen plus daratumumab (dara) and dexamethasone (dex) versus dara in relapsed/refractory multiple myeloma (RRMM) refractory to an immunomodulatory drug (imid) and a proteasome inhibitor (pi) or had received ≥3 prior lines of therapy including an imid and a pi.||María-Victoria Mateos, MD, PhD, from Salamanca’s University Hospital Haematology Department,||Poster P 34|
For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
Cell phone: + 46 70 262 96 28
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.
- Press release – Oncopeptides presents new scientific data at European Myeloma Network MeetingPDF, 0.1 MB